サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1659437

変形性関節症治療薬の世界市場

Osteoarthritis Therapeutics

出版日
ページ情報
英文 84 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
変形性関節症治療薬の世界市場
出版日: 2025年02月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 84 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

変形性関節症治療薬の世界市場は2030年までに158億米ドルに達する見込み

2024年に104億米ドルと推定される変形性関節症治療薬の世界市場は、2024～2030年の分析期間にCAGR 7.3％で成長し、2030年には158億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである膝解剖学は、CAGR 8.1%を記録し、分析期間終了時には71億米ドルに達すると予測されます。股関節解剖学セグメントの成長率は、分析期間でCAGR 7.3％と推定されます。

米国市場は27億米ドルと推定、中国はCAGR10.8％で成長予測

米国の変形性関節症治療薬市場は2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに38億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6%と6.7%と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の変形性関節症治療薬市場- 主要動向と促進要因のまとめ

なぜ変形性関節症治療薬は拡大する健康問題の管理に不可欠なのか？

変形性関節症（OA）治療薬は、この退行性関節疾患に罹患する人口が急増する中、そのニーズに対応するために不可欠なものとなっています。変形性関節症は、関節における軟骨の破壊とその結果生じる炎症によって特徴付けられ、慢性的な痛み、こわばり、運動制限を引き起こし、生活の質に大きな影響を与えます。主に膝、腰、背骨などの体重のかかる関節が侵され、高齢者や肥満の人、関節に損傷を受けた人に特に多く見られます。世界人口の高齢化に伴い、OA症例が急増し、疼痛管理、関節機能の改善、疾患の進行を遅らせる治療薬に対する需要が高まっています。変形性関節症治療薬には、鎮痛薬、非ステロイド性抗炎症薬（NSAIDs）、コルチコステロイド、ヒアルロン酸注射、そして最近では先進的な生物学的治療など、さまざまな治療法が含まれています。

疼痛管理は、OAが高齢者の慢性疼痛の主な原因であることから、変形性関節症治療薬における主要な目的の一つです。非ステロイド性抗炎症薬やアセトアミノフェンは、痛みや炎症を抑える効果があるため広く使用されているが、副作用を伴うことが多く、長期間の使用には限界があります。そのため、副作用を伴わずに持続的な疼痛緩和をもたらす代替治療に対するニーズが高まっており、OA治療薬市場の技術革新を牽引しています。疼痛管理だけでなく、変形性関節症の根本的な原因に対処するための疾患修飾性変形性関節症治療薬（DMOADs）の開発も進んでいます。これらの治療薬は軟骨を保護し、炎症を抑え、関節機能を回復させる可能性があり、OAを管理するためのより包括的なアプローチを提供することを目的としています。長期的な疾患の改善と疼痛緩和に焦点をあてることで、変形性関節症治療薬は重要な研究分野として位置づけられ、症状やQOLのより良い管理を求める患者に希望を与えています。

さらに、OA治療薬は、費用や回復に要する時間、合併症の可能性から最後の手段と見なされがちな人工関節置換術を防ぐという重要な役割を担っています。薬理学的・生物学的治療によってOA症状を効果的に管理することで、手術の必要性を遅らせることができ、患者に侵襲の少ない治療法を提供することができます。このことは、ヘルスケアシステムが選択的手術とそれに伴う費用の負担を減らそうとしている中で、特に重要になってきています。患者に疼痛を緩和し、可動性を改善することで、変形性関節症治療薬は、OAを管理し、疾患の進行を遅らせるための積極的なアプローチをサポートし、患者ができるだけ長く自立し、より質の高い生活を維持できるよう支援します。

先進生物学的療法は変形性関節症治療の未来をどのように形成しているのか？

先進的な生物学的療法の登場は、細胞レベルで疾患を標的とし、その進行を修正する可能性のある治療を導入することで、変形性関節症治療薬の展望を再構築しています。多血小板血漿（PRP）、幹細胞治療、モノクローナル抗体などの生物学的療法は、症状を緩和し、炎症を抑え、損傷した軟骨を再生させる可能性のある新しいアプローチを提供します。患者自身の血液に由来するPRPを患部の関節に注入することで、組織の修復を促進する成長因子によって治癒を促し、炎症を抑えます。間葉系幹細胞を用いる幹細胞療法は、軟骨組織に分化可能な細胞を導入することで軟骨の再生を目指します。まだ実験段階であるが、これらの生物学的製剤は有望な結果をもたらし、OA患者に低侵襲の選択肢を提供し、従来の治療と比較してより長期の効果をもたらす可能性があります。これらの治療法が普及すれば、OAに潜む病態に対処する、より効果的で的を絞った治療が可能になると期待されています。

モノクローナル抗体、特にインターロイキン-1（IL-1）や腫瘍壊死因子（TNF）のような炎症性サイトカインを標的とする抗体は、変形性関節症治療薬におけるもう一つの重要な進歩です。これらの抗体は、軟骨の劣化や関節の炎症の原因となる炎症経路をブロックすることによって機能します。OAに関与する特定のタンパク質を標的とすることで、モノクローナル抗体は、全身的な副作用を最小限に抑え、長期的な緩和をもたらす正確なアプローチを提供します。例えば、インターロイキン-1受容体拮抗薬は、特に変形性膝関節症患者において、炎症を抑え、OAの進行を遅らせる可能性を示しています。このような標的治療薬の有効性が臨床試験で証明され続けていることから、特に重症で進行性の変形性関節症患者にとって、OAを管理する方法を根本的に変える可能性のある疾患修飾治療への期待が高まっています。

遺伝子治療は、変形性関節症治療におけるもう一つの新分野であり、遺伝子発現を変化させて炎症を抑え、軟骨の修復を促すことに焦点を当てています。遺伝子治療は特定の遺伝子を関節組織に導入し、炎症性サイトカインを抑制したり、軟骨の再生を促進したりする治療用タンパク質を産生させる。OAに対する遺伝子治療はまだ初期段階にあるが、1回限りの治療で持続的な緩和と疾患の改善が期待できます。遺伝子治療と個別化医療の融合は、OA治療薬市場の進歩を促進し、疾患の進行に寄与する個々の遺伝的要因に対処する患者特異的治療を提供すると期待されています。これらの生物学的療法が成熟するにつれて、OA治療における個別化・再生アプローチへの変革が進み、従来の治療法では選択肢が限られている患者のアンメット・ニーズに対応することになります。

変形性関節症治療薬は患者やヘルスケアシステムにとってどのような利点がありますか？

変形性関節症治療薬は、慢性疼痛を管理し、関節機能を改善し、自立を維持するのに役立ち、患者にとって大きな利益をもたらします。OAを未治療のままにしておくと、関節の損傷が進行し、痛みが増し、運動機能が著しく制限されることがあるため、効果的なOA管理は、この病気の衰弱を軽減するために不可欠です。疼痛緩和はOA治療薬の主な利点であり、患者は不快感を軽減しながら日常生活を送ることができます。非ステロイド性抗炎症薬（NSAIDs）、副腎皮質ステロイド薬、鎮痛薬は疼痛管理のための一般的な選択肢であり、迅速な緩和をもたらし、患者がより良いQOLを維持できるようにします。重度のOA患者には、ヒアルロン酸のような注射治療が関節の潤滑を与え、摩擦を減らし、衝撃吸収を改善します。痛みや炎症を和らげることで、OA治療薬は関節の健康と全身の健康のために不可欠な身体活動を可能にします。

疼痛管理に加えて、DMOADs、生物学的製剤、再生治療などの新しい変形性関節症治療薬は、疾患の進行を修正し、損傷した関節組織を回復させる可能性を目指しています。これらの治療には、軟骨の劣化を遅らせる、あるいは食い止めるという長期的なメリットがあり、人工関節置換術の必要性を減らし、関節の安定性を向上させる。患者にとっては、侵襲的な処置が減り、回復に要する時間が短縮され、手術やリハビリにかかるヘルスケアコストが削減されることになります。DMOADsは現在も開発中であるが、OAの軌跡を変える治療に対するアンメット・ニーズに応え、患者に症状の緩和以上の選択肢を提供することが期待されています。疾患修飾療法が利用可能になれば、関節機能、可動性、疼痛管理の持続的な改善が期待され、OAケアのより包括的なアプローチが提供されます。

ヘルスケアシステムにとっては、慢性疾患の管理や選択的手術の負担を軽減することで、コスト削減効果が期待できます。人工関節置換術は効果的ではあるが、コストがかかり、ヘルスケア資源に負担をかける。OA治療薬は、OA症状を効果的に管理し、疾患の進行を遅らせることで、特にOAが最も多い高齢者集団において、人工関節置換術の必要性を遅らせたり、あるいは予防したりすることができます。このように手術の必要性が減ることで、ヘルスケア・システムに対するプレッシャーが軽減され、他の必要な分野にリソースを割り当てることができるようになります。さらに、生物学的製剤や個別化治療の進歩により、患者の転帰が改善し、病院での再入院が減少することが期待され、ヘルスケアコストの削減にさらに貢献します。世界中のヘルスケアシステムが慢性疾患管理のための費用対効果の高いソリューションを求める中、変形性関節症治療薬は医療資源配分を最適化しながら患者の転帰を改善する実践的なアプローチを提供します。

変形性関節症治療薬市場の成長を促進しているものは？

変形性関節症治療薬市場の成長は、OA有病率の増加、治療オプションの進歩、低侵襲治療に対する需要の高まり、世界人口の高齢化など、いくつかの重要な要因によってもたらされます。平均寿命が延び続ける中、OA症は、特に関節の変性やその他の加齢関連疾患になりやすい高齢者の間で、より一般的になっています。このような人口動態の変化により、OA治療薬に対する大きな需要が生じており、高齢者はQOLを維持するために効果的な疼痛管理や可動性へのソリューションを求めています。OAが世界中で数百万人に影響を及ぼしていることから、従来の治療法と革新的な治療法の両方に対するニーズが急増し、より効果的で的を絞った治療法の研究開発への投資が促進されています。

特に生物学的製剤の分野における治療法の進歩も、市場の成長を後押ししています。DMOADs、幹細胞治療、モノクローナル抗体の開発は、患者やヘルスケアプロバイダーに症状の緩和を超えた選択肢を提供し、その代わりに病気の経過を変えることを目指しています。これらの先進的な治療法は、病気の進行を遅らせたり、逆行させたりする可能性があり、侵襲的な処置の必要性を減らし、長期にわたる緩和をもたらすことから、患者とヘルスケア専門家の両方から関心を集めています。こうした革新的な治療法は、特に従来の治療法では効果が得られなかった患者にとって魅力的であることから、OA治療薬市場の需要は、より広く利用できるようになり、価格も手頃になるにつれて、さらに高まると予想されます。

さらに、低侵襲手術や患者に特化した治療の動向が、先進的なOA治療薬の採用を後押ししています。患者は、日常生活への支障を最小限に抑えながら効果的な症状管理を提供する治療を求めるようになっています。PRPや幹細胞治療のような生物学的注射は、外来で実施可能な低侵襲性の選択肢を提供することでこの需要に応え、回復までの時間を短縮することを可能にしています。非外科的で低侵襲な治療に対する嗜好の高まりは、製薬会社やヘルスケアプロバイダーに、患者の体感や治療成績を改善するOA代替療法への投資を促しています。さらに、政府の取り組みや新しい治療法に対する保険適用が市場の成長を後押しし、先進的な治療がより多くの患者にとって利用しやすくなると期待されています。高齢化、治療選択肢の進歩、低侵襲治療への需要、医療政策の支援など、これらの要因が相まって、変形性関節症治療薬市場は大きな成長を遂げ、現代ヘルスケアに不可欠なダイナミックな領域へと形成されつつあります。

セグメント

解剖学（膝関節、股関節、手関節、小関節）;薬剤タイプ（関節内補充療法薬、非ステロイド性抗炎症薬、鎮痛薬、副腎皮質ステロイド薬）

調査対象企業の例（注目の23社）

  • Abbott
  • Anika Therapeutics
  • Bayer AG
  • Bioventus
  • Eli Lilly
  • Fidia Farmaceutici s.p.a.
  • Flexion Therapeutics
  • GlaxoSmithKline Plc
  • Horizon Therapeutics
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi
  • Zimmer Biomet Holdings, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22441

Global Osteoarthritis Therapeutics Market to Reach US$15.8 Billion by 2030

The global market for Osteoarthritis Therapeutics estimated at US$10.4 Billion in the year 2024, is expected to reach US$15.8 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Knee Anatomy, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Hip Anatomy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 10.8% CAGR

The Osteoarthritis Therapeutics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Osteoarthritis Therapeutics Market - Key Trends & Drivers Summarized

Why Are Osteoarthritis Therapeutics Critical in Managing a Growing Health Concern?

Osteoarthritis (OA) therapeutics have become essential in addressing the needs of a rapidly growing population affected by this degenerative joint disease. Osteoarthritis, characterized by the breakdown of cartilage and the resultant inflammation in joints, leads to chronic pain, stiffness, and mobility limitations that significantly impact quality of life. It primarily affects weight-bearing joints like the knees, hips, and spine, and is especially prevalent among the aging population, as well as individuals with obesity or those who have sustained joint injuries. As the global population ages, OA cases have surged, creating an increased demand for therapeutics that can manage pain, improve joint function, and slow disease progression. Osteoarthritis therapeutics encompass a range of treatments, including analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, hyaluronic acid injections, and, more recently, advanced biological treatments.

Pain management is one of the primary objectives in osteoarthritis therapeutics, as OA is a leading cause of chronic pain among older adults. NSAIDs and acetaminophen are widely used for their effectiveness in reducing pain and inflammation, but they often come with side effects that limit their long-term use. As a result, there is a growing need for alternative treatments that offer sustainable pain relief without adverse effects, driving innovation in the OA therapeutics market. Beyond pain management, disease-modifying osteoarthritis drugs (DMOADs) are increasingly being developed to address the underlying causes of OA. These therapies aim to protect cartilage, reduce inflammation, and potentially restore joint function, offering a more comprehensive approach to managing OA. The focus on long-term disease modification and pain relief has positioned osteoarthritis therapeutics as a crucial area of research, providing hope for patients seeking better management of their symptoms and quality of life.

Additionally, OA therapeutics play a critical role in preventing joint replacement surgeries, which are often seen as a last resort due to the costs, recovery time, and potential complications involved. Effective management of OA symptoms through pharmacological and biological treatments can delay the need for surgery, providing patients with less invasive options for managing their condition. This has become especially important as healthcare systems seek to reduce the burden of elective surgeries and their associated costs. By offering patients relief from pain and improved mobility, osteoarthritis therapeutics support a proactive approach to managing OA and delaying disease progression, helping patients maintain independence and a higher quality of life for as long as possible.

How Are Advanced Biological Therapies Shaping the Future of Osteoarthritis Treatment?

The advent of advanced biological therapies is reshaping the osteoarthritis therapeutics landscape by introducing treatments that target the disease at a cellular level, with the potential to modify its progression. Biological therapies, including platelet-rich plasma (PRP), stem cell therapy, and monoclonal antibodies, offer new approaches for alleviating symptoms, reducing inflammation, and potentially regenerating damaged cartilage. PRP, derived from the patient’s own blood, is injected into the affected joint to stimulate healing and reduce inflammation through growth factors that promote tissue repair. Stem cell therapy, which uses mesenchymal stem cells, aims to regenerate cartilage by introducing cells capable of differentiating into cartilage tissue. Although still in the experimental stage, these biologics offer promising results, providing OA patients with minimally invasive options that may offer longer-lasting benefits compared to traditional treatments. As these therapies gain traction, they are expected to provide more effective, targeted treatments that address OA’s underlying pathology.

Monoclonal antibodies, specifically those targeting inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor (TNF), represent another significant advancement in osteoarthritis therapeutics. These antibodies work by blocking the inflammatory pathways that contribute to cartilage degradation and joint inflammation. By targeting specific proteins involved in OA, monoclonal antibodies offer a precise approach that minimizes systemic side effects and provides long-term relief. For example, interleukin-1 receptor antagonists have shown potential in reducing inflammation and slowing the progression of OA, especially in patients with knee osteoarthritis. As clinical trials continue to demonstrate the efficacy of these targeted therapies, they offer hope for disease-modifying treatments that could fundamentally change how OA is managed, particularly for patients with severe and progressive forms of the disease.

Gene therapy is another emerging field in osteoarthritis treatment, focusing on altering gene expression to reduce inflammation and stimulate cartilage repair. Gene therapies introduce specific genes into joint tissues to produce therapeutic proteins that may inhibit inflammatory cytokines or enhance cartilage regeneration. Although gene therapy for OA is still in its early stages, it holds the potential for one-time treatments that could offer sustained relief and disease modification. The convergence of gene therapy and personalized medicine is expected to drive advancements in the OA therapeutics market, providing patient-specific treatments that address individual genetic factors contributing to disease progression. As these biological therapies mature, they represent a transformative shift toward personalized and regenerative approaches in OA treatment, addressing the unmet needs of patients who have limited options with conventional therapies.

What Are the Benefits of Osteoarthritis Therapeutics for Patients and Healthcare Systems?

Osteoarthritis therapeutics offer significant benefits for patients, helping them manage chronic pain, improve joint function, and maintain their independence. Effective OA management is essential for reducing the debilitating effects of the disease, as untreated OA can lead to progressive joint damage, increased pain, and severe mobility limitations. Pain relief is a primary benefit of OA therapeutics, allowing patients to engage in daily activities with reduced discomfort. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics remain popular choices for pain management, offering quick relief and allowing patients to maintain a better quality of life. For patients with severe OA, injectable treatments like hyaluronic acid provide joint lubrication, reduce friction, and improve shock absorption, thereby reducing pain and improving function for several months. By alleviating pain and inflammation, OA therapeutics enable patients to engage in physical activity, which is essential for joint health and overall well-being.

In addition to pain management, newer osteoarthritis therapeutics, such as DMOADs, biologics, and regenerative treatments, aim to modify disease progression and potentially restore damaged joint tissues. These treatments offer the long-term benefit of slowing or halting cartilage degradation, which reduces the need for joint replacement surgeries and improves joint stability. For patients, this means fewer invasive procedures, shorter recovery times, and reduced healthcare costs associated with surgery and rehabilitation. DMOADs, still in development, are expected to address the unmet need for treatments that alter OA’s trajectory, providing patients with options that go beyond symptom relief. As disease-modifying therapies become available, they promise to deliver durable improvements in joint function, mobility, and pain management, offering a more comprehensive approach to OA care.

For healthcare systems, osteoarthritis therapeutics provide cost-saving benefits by reducing the burden of chronic disease management and elective surgeries. Joint replacement surgeries, though effective, are costly and place strain on healthcare resources. By managing OA symptoms effectively and slowing disease progression, OA therapeutics can delay or even prevent the need for joint replacement surgeries, particularly in aging populations where OA is most prevalent. This reduction in surgical demand alleviates pressure on healthcare systems and allows resources to be allocated to other areas of need. Additionally, advances in biologics and personalized treatments are expected to improve patient outcomes and reduce hospital readmissions, which further contributes to healthcare cost savings. As healthcare systems worldwide seek cost-effective solutions for managing chronic conditions, osteoarthritis therapeutics offer a practical approach to improving patient outcomes while optimizing healthcare resource allocation.

What Is Fueling the Growth in the Osteoarthritis Therapeutics Market?

The growth in the osteoarthritis therapeutics market is driven by several key factors, including the increasing prevalence of OA, advances in therapeutic options, rising demand for minimally invasive treatments, and an aging global population. As life expectancy continues to rise, OA has become more common, particularly among older adults who are prone to joint degeneration and other age-related conditions. This demographic shift has created a substantial demand for OA therapeutics, as aging individuals seek effective pain management and mobility solutions to maintain their quality of life. With OA affecting millions globally, the need for both traditional and innovative treatments has surged, driving investments in research and development for more effective and targeted therapies.

Advances in therapeutic options, particularly in the field of biologics, are also propelling market growth. The development of DMOADs, stem cell therapies, and monoclonal antibodies provides patients and healthcare providers with options that go beyond symptom relief, aiming instead to alter the course of the disease. These advanced therapies have garnered interest from both patients and healthcare professionals, as they offer the potential to slow or reverse disease progression, reducing the need for invasive procedures and providing long-lasting relief. The appeal of these innovative therapies, especially among patients who have not responded to conventional treatments, is expected to fuel demand in the OA therapeutics market as they become more widely available and affordable.

Furthermore, the trend toward minimally invasive procedures and patient-specific treatments is driving the adoption of advanced OA therapeutics. Patients are increasingly seeking treatments that offer effective symptom management with minimal disruption to their daily lives. Biological injections, such as PRP and stem cell therapy, meet this demand by providing minimally invasive options that can be administered in outpatient settings, allowing for quicker recovery times. This growing preference for non-surgical and minimally invasive treatments has encouraged pharmaceutical companies and healthcare providers to invest in alternative OA therapies that improve patient experience and outcomes. Additionally, government initiatives and insurance coverage for newer therapies are expected to support market growth, making advanced treatments more accessible to a broader patient population. Together, these factors—the aging population, advancements in therapeutic options, demand for minimally invasive treatments, and supportive healthcare policies—are driving significant growth in the osteoarthritis therapeutics market, shaping it into a dynamic and essential area of modern healthcare.

SCOPE OF STUDY:

The report analyzes the Osteoarthritis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Anatomy (Knee, Hip, Hand, Small Joints); Drug Type (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 23 Featured) -

  • Abbott
  • Anika Therapeutics
  • Bayer AG
  • Bioventus
  • Eli Lilly
  • Fidia Farmaceutici s.p.a.
  • Flexion Therapeutics
  • GlaxoSmithKline Plc
  • Horizon Therapeutics
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi
  • Zimmer Biomet Holdings, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Osteoarthritis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Osteoarthritis Drives Demand for Therapeutics
    • Increasing Focus on Pain Management Propels Osteoarthritis Therapeutics Market
    • Advancements in Biologics and Stem Cell Therapies Expand Market Potential
    • Growing Adoption of Disease-Modifying Osteoarthritis Drugs (DMOADs) Sets the Stage for Market Growth
    • Innovations in Oral, Topical, and Injectable Therapies Propel Demand
    • Increasing Elderly Population Generates Demand for Osteoarthritis Treatment Solutions
    • Growing Interest in Non-Opioid Pain Management Expands Market Opportunities
    • Surge in Minimally Invasive Procedures Spurs Osteoarthritis Therapeutic Adoption
    • Adoption of Alternative Therapies Expands Treatment Options for Osteoarthritis
    • Increasing Demand for Over-the-Counter (OTC) Osteoarthritis Drugs Propels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Osteoarthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Knee by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Knee by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Knee by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hip by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hip by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hip by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Hand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Hand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Small Joints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Small Joints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Small Joints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Viscosupplementation Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Viscosupplementation Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Viscosupplementation Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Osteoarthritis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • JAPAN
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • CHINA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • EUROPE
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Osteoarthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • FRANCE
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • GERMANY
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • INDIA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Osteoarthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Osteoarthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • AFRICA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030

IV. COMPETITION